Floatz logo

OMBURTAMAB

Peritoneal Cancer

Memorial Sloan Kettering Cancer Centermonoclonal_antibodyPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
81/ 100

Competitive context

36 Active assets in the Peritoneal Cancer cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
Peking University
Phase 2BB
Docetaxel
University of Pittsburgh
Phase 2BB
FLUOROURACILUM
City of Hope Medical Center
Phase 3BB
Mirvetuximab Soravtansine
AbbVie
Phase 3BB
Carboplatin
Qilu Hospital of Shandong University
Phase 3BB

View all 50 →

Same molecule, other indications

OMBURTAMAB is also rated in:

desmoplastic small round cell tumorDormant
CCC
Indicative ·
53 / 100
View asset →
peritoneal carcinomaDormant
CCC
Indicative ·
53 / 100
View asset →
neoplastic meningitisDormant
CC
Indicative ·
45 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →